酒精性肝硬化全基因组关联研究识别MARC1与HNRNPUL1风险位点
基于英国生物银行35,839名高酒精摄入参与者的全基因组关联研究,以肝纤维化标志物和转氨酶为指标筛选位点,并在5个欧洲队列中验证。发现MARC1:rs2642438次要A等位基因降低酒精性肝硬化风险(校正OR 0.76),HNRNPUL1:rs15052次要C等位基因增加风险(校正OR 1.30)。
要点
- MARC1:rs2642438次要A等位基因与酒精性肝硬化风险降低相关,校正OR 0.76(P=.0027)。
- HNRNPUL1:rs15052次要C等位基因与酒精性肝硬化风险升高相关,校正OR 1.30(P=.020)。
- 发现阶段50个全基因组显著位点,9个在1期验证显著,其中6个在2期验证显著。
核心结论
- 在英国生物银行样本的全基因组关联研究中识别并在5个欧洲队列中验证了影响酒精性肝硬化风险的单核苷酸多态性,MARC1:rs2642438次要A等位基因降低风险,HNRNPUL1:rs15052次要C等位基因增加风险。
研究设计与样本
- 对英国生物银行35,839名高酒精摄入参与者进行全基因组关联研究,以肝纤维化标志物(FIB-4、APRI、Forns指数评分)和转氨酶水平为指标。
- 发现阶段识别的位点在3个独立欧洲队列(1期验证队列,n=2545)中检验与酒精性肝硬化的关联。
- 在1期验证中以错误发现率低于20%与酒精性肝硬化相关的变异,在2个额外欧洲验证队列(2期验证,n=2068)中直接基因分型。
主要发现
- 发现阶段全基因组关联研究识别50个独立风险位点达到全基因组显著性(P < 5 × 10-8)。
- 50个位点中9个在1期验证队列中与酒精性肝硬化显著相关。
- 9个位点中6个在2期验证队列中以错误发现率低于5%与酒精性肝硬化显著相关。
- 2期验证队列中调整年龄、性别、体重指数和2型糖尿病后,MARC1:rs2642438次要A等位基因与酒精性肝硬化风险降低相关(校正OR 0.76;P=.0027)。
- 2期验证队列中调整年龄、性别、体重指数和2型糖尿病后,HNRNPUL1:rs15052次要C等位基因与酒精性肝硬化风险增加相关(校正OR 1.30;P=.020)。
关键数值与推荐
- 发现阶段全基因组显著性阈值为P < 5 × 10-8。
- 1期验证中与酒精性肝硬化关联的错误发现率阈值为低于20%。
- 2期验证中与酒精性肝硬化关联的错误发现率阈值为低于5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Little is known about genetic factors that affect development of alcohol-related cirrhosis. We performed a genome-wide association study (GWAS) of samples from the United Kingdom Biobank (UKB) to identify polymorphisms associated with risk of alcohol-related liver disease. METHODS: We performed a GWAS of 35,839 participants in the UKB with high intake of alcohol against markers of hepatic fibrosis (FIB-4, APRI, and Forns index scores) and hepatocellular injury (levels of aminotransferases). Loci identified in the discovery analysis were tested for their association with alcohol-related cirrhosis in 3 separate European cohorts (phase 1 validation cohort; n=2545). Variants associated with alcohol-related cirrhosis in the validation at a false discovery rate of less than 20% were then directly genotyped in 2 additional European validation cohorts (phase 2 validation, n=2068). RESULTS: In the GWAS of the discovery cohort, we identified 50 independent risk loci with genome-wide significance (P < 5 × 10-8). Nine of these loci were significantly associated with alcohol-related cirrhosis in the phase 1 validation cohort; 6 of these 9 loci were significantly associated with alcohol-related cirrhosis in phase 2 validation cohort, at a false discovery rate below 5%. The loci included variants in the mitochondrial amidoxime reducing component 1 gene (MARC1) and the heterogeneous nuclear ribonucleoprotein U like 1 gene (HNRNPUL1). After we adjusted for age, sex, body mass index, and type-2 diabetes in the phase 2 validation cohort, the minor A allele of MARC1:rs2642438 was associated with reduced risk of alcohol-related cirrhosis (adjusted odds ratio, 0.76; P=.0027); conversely, the minor C allele of HNRNPUL1:rs15052 was associated with an increased risk of alcohol-related cirrhosis (adjusted odds ratio, 1.30; P=.020). CONCLUSIONS: In a GWAS of samples from the UKB, we identified and validated (in 5 European cohorts) single-nucleotide polymorphisms that affect risk of alcohol-related cirrhosis in opposite directions: the minor A allele in MARC1:rs2642438 decreases risk, whereas the minor C allele in HNRNPUL1:rs15052 increases risk.
引用
- Innes H, Buch S, Hutchinson S, et al. Genome-Wide Association Study for Alcohol-Related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1. Gastroenterology. 2020. PMID: 32561361. doi:10.1053/j.gastro.2020.06.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。